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Abstract
Background and purpose: To investigate the incorporation of data from single-photon emission
computed tomography (SPECT) or hyperpolarized helium-3 magnetic resonance imaging (3He-
MRI) into intensity-modulated radiotherapy (IMRT) planning for non-small cell lung cancer
(NSCLC).
Material and methods: Seven scenarios were simulated that represent cases of NSCLC with
significant functional lung defects. Two independent IMRT plans were produced for each scenario;
one to minimise total lung volume receiving ≥20 Gy (V20), and the other to minimise only the
functional lung volume receiving ≥20 Gy (FV20). Dose–volume characteristics and a plan quality
index related to planning target volume coverage by the 95% isodose (VPTV95/FV20) were compared
between anatomical and functional plans using the Wilcoxon signed ranks test.
Results: Compared to anatomical IMRT plans, functional planning reduced FV20 (median 2.7%,
range 0.6–3.5%, p = 0.02), and total lung V20 (median 1.5%, 0.5–2.7%, p = 0.02), with a small
reduction in mean functional lung dose (median 0.4 Gy, 0–0.7 Gy, p = 0.03). There were no significant
differences in target volume coverage or organ-at-risk doses. Plan quality index was improved for
functional plans (median increase 1.4, range 0–11.8, p = 0.02).
Conclusions: Statistically significant reductions in FV20, V20 and mean functional lung dose are
possible when IMRT planning is supplemented by functional information derived from SPECT
or 3He-MRI.
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Intensity-modulated radiotherapy; Non-small cell lung cancer; SPECT; Hyperpolarized helium-3
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Radical radiotherapy plays a significant role in the curative management of medically or
surgically inoperable non-small cell lung cancer patients, with 5-year survival rates of 29–42%
for stage I–II disease [1,2] and 5–14% for locally advanced stage IIIA–B tumours [3,4]. Dose
escalation may improve tumour control and survival [5,6], but is limited by the incidence of
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radiation pneumonitis, a dose- and volume-dependent effect that correlates with the mean lung
dose (MLD) and the volume of lung receiving a dose of at least 20 Gy (V20). This risk of
radiation pneumonitis can be reduced by up to 10% using intensity-modulated radiotherapy
(IMRT), without compromise in tumour dose delivery [7,8].
IMRT planning has traditionally been performed with the assumption that functional activity
is distributed homogeneously throughout the lung. However, a significant proportion of
NSCLC patients have defects in regional lung function caused either by local tumour effects
or by concurrent pulmonary disease [9–12]. This observation has prompted investigations of
functional image-based radiotherapy planning, utilising physiological information from either
single-photon emission computed tomography (SPECT) [10–13], four-dimensional X-ray
computed tomography (4D-CT) [14] or hyperpolarized helium-3 magnetic resonance imaging
(3He-MRI) [15,16].
The use of perfusion SPECT in facilitating lung radiotherapy treatment planning has been
investigated over a number of years, with results demonstrating that incorporation of SPECT
functional information into standard conformal radiotherapy planning can allow reductions in
the V20 for functional lung (FV20) of 3–17% in individual cases, particularly where discrete
non-functional regions of significant size are detected [10,17]. In addition, the combination of
SPECT imaging data with IMRT techniques has shown the potential to improve functional
lung avoidance when compared to both SPECT-based 3D conformal plans [11], and standard
anatomical IMRT plans [12,13], permitting average reductions in FV20 of 3–10.6% in patients
with locally advanced disease, although this benefit has not been demonstrable in early stage
patients [11–13].
Alternative functional imaging approaches that have been utilised in this setting include
emerging forms of MRI in which inert hyperpolarized helium-3 gas is inhaled to demonstrate
regional lung function by selective display of ventilated air spaces, with signal voids
corresponding to non-ventilated regions. 3He-MRI avoids the need for additional radiation
exposure whilst providing ventilation distribution images comparable to nuclear medicine
techniques, and can be co-registered with conventional CT for radiotherapy treatment planning
[15,16,18]. Evaluation of lung ventilation has also been proposed through observation of
changes in the pulmonary parenchyma across the respiratory cycle using 4D-CT [14].
Both 3He-MRI and 4D-CT have been combined with IMRT planning, allowing reductions in
FV20 of between 1% and 3% in preliminary studies [14,18].
Existing studies have identified the potential utility of functional imaging in radiotherapy
planning, but have provided differing suggestions as to the situations where it may be most
useful. Early SPECT studies using conformal planning concluded that the greatest benefits
were observed in patients with large localised defects in lung function [10,17], a view supported
by the findings of a more recent study using IMRT [12]. However, another recent study
comparing SPECT-based IMRT with functional 3D conformal planning failed to identify
significant benefits in this group, suggesting instead diffuse inhomogeneity of lung function
as the most favourable setting for the use of this combined technique [11,19].
The aim of this study was to investigate the impact of incorporating ventilation and perfusion
data in the design of IMRT plans for the radical treatment of NSCLC. Specifically, the objective
was to use simulated functional image data to investigate which patient groups may benefit
most from functional image-based planning. To achieve this, we compared IMRT plans
produced with and without the inclusion of functional data for a number of clinical scenarios
that represent cases of locally advanced lung cancer with significant functional lung deficits.
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Materials and methods
Simulated clinical scenarios
A breath-hold CT image volume from a patient participating in a related 3He-MRI lung
planning study [20] was chosen as a base to generate the NSCLC simulations. The selected
CT demonstrated essentially normal pulmonary and mediastinal anatomy, without extensive
distortion due to pathology or primary tumour. The CT was imported into AdvantageSim
treatment planning software (GE Healthcare, Princeton, NJ, USA) for contouring, and was
used to create seven scenarios using simulated functional imaging data representing locally
advanced NSCLC of stage IIIA–B, covering a range of primary tumours sites and involved
nodal groups. Each scenario considered a central primary tumour location in which the presence
of regional lobar or multi-lobar functional deficits in distal or adjacent lung could be expected.
The seven simulated cases are summarised in Fig. 1.
For each scenario, a gross tumour volume (GTV) was delineated on the CT images to include
the simulated primary tumour and involved nodal groups. This was then expanded by 5 mm
in all dimensions to arrive at the clinical target volume (CTV), and then further expanded by
10 mm circumferentially and 15 mm in the cranio-caudal direction to define the planning target
volume (PTV), as per local protocols. In addition, the spinal cord, oesophagus, heart, and
external patient contours were outlined, and the total lung volume was contoured as the entire
ipsilateral and contralateral lung volume excluding the GTV.
A further structure was then created for each simulation to represent the functional lung volume.
This used anatomical lobar boundaries identified on the CT dataset to simulate lobar or multi-
lobar functional defects congruous with the primary tumour characteristics. Finally, a “normal
tissue” structure was defined, using the PTV subtracted from the external patient contour, to
generate an avoidance structure for use in limiting normal tissue low-dose irradiation. Once
contoured, all simulation scenarios were reviewed prior to use in IMRT planning by a clinical
oncology consultant experienced in the management of lung cancer and with knowledge
of 3He-MRI distributions, to ensure clinical relevance and realism, plus congruence of GTVs
with simulated defects.
IMRT planning
All simulations were imported into the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA, USA) for IMRT planning. Plans were created using five isocentric,
coplanar, non-opposing beams, with manually optimised incident beam angles and
arrangements for each individual anatomical or functional plan. Inverse planning was
performed to generate treatment beam fluence intensity maps using the Eclipse Dose-Volume-
Optimiser module, with planned IMRT delivery via the dynamic MLC method.
For each simulated scenario, two independent treatment plans were produced. Firstly, an
anatomical plan was created, with beam angles and beamlet fluence optimised with the
intention of mini-mising the total lung volume receiving ≥20 Gy (V20). Secondly, a functional
plan was generated that minimised the volume of identified functional lung receiving ≥20 Gy
(FV20). Additional constraints were included in all inverse planning optimisations to produce
plans meeting the requirements detailed in Table 1, with sequential priority given to achieving
planning target volume coverage, limiting spinal cord dose, achieving lung dose–volume
optimisation goals, and remaining within normal tissue dose-constraints.
Following optimisation, forward dose calculation was performed for each plan to generate an
accurate dose distribution, using the eclipse anisotropic analytical algorithm (AAA) with
inhomogeneity correction [21]. All plans were designed for delivery using 6 MV photons, to
a prescribed CHART dose of 54 Gy in 36 fractions [22]. In addition to standard dose
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distributions, dose–volume histograms were created for all plans to aid assessment of dose–
volume parameters.
For each plan, the following were calculated and recorded:
• VPTV95 (percentage volume of the PTV covered by the 95% isodose)
• minimum and maximum doses within the PTV
• maximum spinal cord dose
• V20 (percentage of total lung volume receiving ≥20 Gy)
• FV20 (percentage of functional lung volume receiving ≥20 Gy)
• MLD (mean lung dose for total lung in Gy)
• MFLD (mean functional lung dose in Gy)
• V45 for heart (percentage volume of heart receiving ≥45 Gy)
• V55 for oesophagus (percentage of oesophageal volume receiving ≥55 Gy)
• maximum normal tissue dose
• monitor units (MUs) required to deliver the IMRT plan on a Varian linear accelerator.
Where there was a choice between two or more clinically acceptable alternative plans, the ratio
of VPTV95:V20, or VPTV95:FV20, was used to select the “best” overall arrangement for
anatomical or functional plans, respectively, with a higher ratio representing a “better” plan
that has proportionally less lung irradiation for a given level of PTV coverage.
Data analysis and statistical methods
Data collected for the two plan groups were summarised using the median and range, and
differences between the two groups were assessed for significance using the Wilcoxon signed
ranks test. All statistical analysis was performed using SPSS for Windows (SPSS Version 15.0;
Chicago, IL, USA). A p value less than 0.05 was considered statistically significant.
Results
The characteristics of the seven scenarios generated for use in treatment planning simulation
are outlined in Table 2. The median PTV for simulated NSCLC scenarios was 599.8 cm3 (range
361.4–669.2 cm3) with a median functional lung deficit comprising 25.0% (19.4–55.2%) of
the total lung volume.
Clinically acceptable plans that fulfilled the criteria for limitation of dose to lung, heart,
oesophagus, spinal cord, and normal tissue were achieved for all scenarios using both the
anatomical and functional optimisation strategies. All plans met the requirements for target
volume dose prescription as previously described, with dose–volume characteristics for the
anatomical and functional plan groups as summarised in Table 3.
In all seven scenarios, the inclusion of functional information in the optimisation process
resulted in reduced dose–volume parameters for functional lung when compared to plans
produced with anatomical information alone, with reductions in the FV20 for each case, and a
median reduction in FV20 of 2.7% (range 0.6–3.5%, p = 0.02). Furthermore, a small but
statistically significant reduction in the mean functional lung dose (MFLD) of 0.4 Gy (0–0.7
Gy, p = 0.03) was observed in favour of the functional plan group.
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In addition to the demonstrated reduction in functional lung irradiation volume, plans optimised
using both anatomical and functional information showed a reduction in the total lung V20
(median reduction 1.5%, range 0.5–2.7%, p = 0.02) when compared to purely anatomical plans.
However, this did not translate into reduced mean total lung doses, with median values of 13.8
Gy for both plan groups.
Improvements in FV20 were achieved without necessitating compromise of target volume
coverage, with no significant differences in VPTV95 observed between the anatomical and
functional plan groups, with median values of 91.8% (range 90.4–93.2%) and 91.4% (range
90.2–93.2%), respectively (p = 1.00). Use of the VPTV95:FV20 ratio as an overall plan quality
index showed a benefit in favour of the functionally optimised plans, with higher ratios
recorded for the functional group, indicating more favourable plans (median increase in ratio
1.4, range 0–11.8, p = 0.02).
There were no significant differences in the number of monitor units required to deliver the
anatomically and functionally optimised plans (median 556 MU vs. 592 MU, p = 0.55) nor
were significant variations seen in maximum spinal cord dose (median 37.2 Gy vs. 24.3 Gy,
p = 0.3), V45 volume for heart (median 3.8% vs. 3.8%, p = 0.7), or the oesophageal V55 volume
(medians 22.9% vs. 21.1%, p = 0.2).
Discussion
Functional imaging modalities such as SPECT and 3He-MRI can be accurately co-registered
to standard CT planning images to provide combined datasets for treatment planning, and
previous studies suggest potential improvements in functional lung dose–volume parameters
when this information is utilised in IMRT planning. However, these techniques are not yet
widely available in the UK, and routine application to clinical practice would carry significant
resource implications. Therefore, identification of the patient groups who are most likely to
benefit from these new and evolving techniques is important, to help direct resources
appropriately.
The principal aim of this study was to assess the impact of incorporating functional information
into IMRT planning for the radical treatment of NSCLC on lung dose–volume parameters.
Seven scenarios using simulated functional imaging data representing locally advanced
NSCLC have demonstrated that inclusion of functional information in IMRT plan optimisation
allowed improved avoidance of functional lung, as assessed by FV20 and the MFLD, compared
to anatomical IMRT alone. The median reduction in FV20 of 2.7% demonstrated in this
simulation study is in keeping with that observed previously by Ireland et al of 3.1% (range
0.4–5.1%) [18] when using 3He-MRI data, although it is less than the 5–6% absolute median
reductions in FV20 observed in selected SPECT literature examining functional versus
anatomical IMRT [12,13].
Observed improvements in FV20 and MLFD were achieved without compromise in target
volume coverage, with an overall increase in the plan quality index for the functional plan
group. In addition, there were no significant changes in the doses received by critical normal
structures such as heart, spinal cord, and oesophagus. This indicates that this technique could
be safely applied to patient treatments, without exceeding known normal tissue tolerances or
compromising anti-tumour efficacy.
In addition to improvements in functional lung dose–volume parameters observed in this study,
small improvements in total lung V20 volumes were identified, which have also been found by
previous groups investigating functional radiotherapy planning [12,18]. A possible explanation
for this improvement in V20 may be an increased degree of freedom allowed to the planning
algorithm when only functional lung doses are constrained, permitting distribution of total lung
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dose into not only low-dose zones, but also zones of non-functional lung where the 20 Gy
threshold has already been exceeded, due to calculation of cost functions in inverse planning
via an “area under the curve” method.
The largest improvements in FV20 and plan quality ratio (VPTV95:FV20) were seen in Scenarios
3, 5, 6 and 7, with observed reductions of 2.7–3.5%, as compared to smaller differences of
≤1.4% in other case simulations. Examination of the characteristics of these simulations
suggests that the size of the functional deficit identified could be an important factor in
determining the value of the functional information in treatment planning, with scenarios where
defects exceeded approximately 25% of the total lung volume showing larger potential
reductions in FV20. This is in keeping with the findings of previous SPECT studies, such as
that performed by Seppenwoolde et al. [10], who demonstrated greater improvements in
functional lung irradiation parameters with large functional deficits, hypothesising that larger
non-functional volumes allow greater potential to select beam arrangements that enter or exit
through a non-functional “window” of lung.
Although the reductions in FV20 and MFLD observed in the study simulations are statistically
significant, it is not clear whether such reductions in FV20 volume would have clinical relevance
in terms of reduction of the risk of pulmonary morbidity for patients. In addition, there is
currently a lack of outcome data correlating functional lung dose–volume parameters with
pulmonary toxicity endpoints, and no generally accepted functional lung planning constraints
exist in the literature. This is clinically relevant as evidence suggests that a proportion of
functional deficits identified prior to radiotherapy may undergo recovery after successful
treatment of the primary tumour [9], for example restoration of perfusion or ventilation to a
segment of lung previously impaired by compression due to local tumour. Such recovery could
conceivably diminish the toxicity of standard anatomically planned treatments that limit the
dose to total lung V20, but may not be possible if the potentially recoverable lung had received
a higher radiation dose due to classification as non-functional on pre-treatment imaging.
Ongoing work at this institution aims to address these issues, with long-term follow-up of a
preliminary patient cohort for whom functional lung dose–volume parameters are known, with
assessment of lung function and morbidity outcomes after radical radiotherapy treatment, and
comparison of baseline and follow-up functional 3He-MRI scans.
In this study, a limited number of simulated functional defects were examined, each consisting
of a relatively large, localised lobar or multi-lobar functional deficit that correlated with the
simulated tumour position. These defects were selected to represent a subgroup of situations
in NSCLC that could be potentially favourable for functional planning based on previous
published work, and are not representative of the entire NSCLC patient spectrum. A previous
radiotherapy planning series utilising perfusion SPECT has demonstrated that such localised
functional deficits are present in a significant proportion of patients undergoing radiotherapy
for NSCLC, with even large deficits such as hypo-function of the entire ipsilateral lung present
in 16% of cases [10]. However, a significant number of patients had defects only at the target
tumour itself, or varied patterns of inhomogeneous function spread throughout the lung, and
therefore whilst it is likely that these simulations correspond to patterns present in real NSCLC
patients, they may only be a small subset of the population as a whole.
Considerable further work is required before this technique could be considered for routine
application. The first step would be application of 3He-MRI- or SPECT-based planning to a
larger cohort of NSCLC patients undergoing radiotherapy, to assess if reductions in functional
lung dose–volume parameters can be consistently achieved in real patients. This could also
allow analysis of the potential factors that may predict the utility of functional planning and
allow patient selection, such as the size of functional defects, PTV, tumour stage, or even pre-
treatment pulmonary function test parameters. In addition, work is required to demonstrate that
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reductions in functional lung dose parameters will translate into clinical benefits for NSCLC
patients.
Conclusion
This study demonstrates that reductions in FV20, V20 and MFLD are possible for a subset of
locally advanced NSCLC patients when standard IMRT planning techniques are supplemented
by simulated functional lung imaging information such as that derived from 3He-MRI or
SPECT. The greatest benefits may be seen in patients who have larger localised functional
defects.
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Fig. 1.
Summary of simulated non-small-cell lung cancer scenarios. The figures demonstrate the target
and normal tissues contours for the seven simulated scenarios, demonstrating structures as
indicated by the colour key. Scenarios incorporated non-functional lung regions comprising:
(1) left upper lobe; (2) left lower lobe; (3) whole left lung; (4) right upper lobe; (5) right lower
lobe; (6) whole right lung; and (7) right middle and lower lobe (simulating primary lesion of
bronchus intermedius.).
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Table 1
IMRT plan constraints.
Structure Constraint
Planning target volume (PTV) Mean dose 54 Gy, and ≥90% of PTV receiving 95% or more
of the prescribed dose
Spinal cord Maximum point dose ≤40 Gy
Totala or functionalb lung Volume receiving ≥20 Gy less than 35%
Oesophagus Volume receiving ≥55 Gy less than 35%
Heart Volume receiving ≥45 Gy less than 50%
Normal tissue Maximum point dose ≤60 Gy
a
For anatomical plans.
b
For functional plans.
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